Page last updated: 2024-12-06
taltrimide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 71248 |
| CHEMBL ID | 2107479 |
| SCHEMBL ID | 347001 |
| MeSH ID | M0135727 |
Synonyms (25)
| Synonym |
|---|
| taltrimide |
| 2-(1,3-dioxoisoindol-2-yl)-n-propan-2-ylethanesulfonamide |
| 81428-04-8 |
| n-isopropyl-1,3-dioxo-2-isoindolineethanesulfonamide |
| unii-nq74u9qr5d |
| 2h-isoindole-2-ethanesulfonamide, 1,3-dihydro-n-(1-methylethyl)-1,3-dioxo- |
| taltrimida [spanish] |
| taltrimidum [latin] |
| taltrimida |
| nq74u9qr5d , |
| taltrimide [inn] |
| taltrimidum |
| CHEMBL2107479 |
| SCHEMBL347001 |
| AKOS016487334 |
| NZKNHIQZWSVJGP-UHFFFAOYSA-N |
| 2-(1,3-dioxoisoindolin-2-yl)-n-isopropyl-ethanesulfonamide |
| 2-(1,3-dioxoisoindolin-2-yl)-n-isopropylethanesulfonamide |
| F2834-0106 |
| my 117 |
| Q27284993 |
| 2-(1,3-dioxo-1,3-dihydro-2h-isoindol-2-yl)-n-(propan-2-yl)ethane-1-sulfonamide |
| DTXSID50868612 |
| 2-(1,3-dioxoisoindolin-2-yl)-n-isopropylethane-1-sulfonamide |
| 2-(1,3-dioxoisoindol-2-yl)-n-isopropylethanesulfonamide |
Research Excerpts
Overview
Taltrimide is a lipophilic taurine derivative with definitive anticonvulsive effects in experimental epilepsy models.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Taltrimide is a lipophilic taurine derivative with definitive anticonvulsive effects in experimental epilepsy models. " | ( Effects of taltrimide, an experimental taurine derivative, on photoconvulsive response in epileptic patients. Keränen, T; Koivisto, K; Neuvonen, PJ; Partanen, VS; Riekkinen, PJ; Tokola, O, ) | 1.96 |
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pretreatment with taltrimide, a lipophilic taurine derivative (intraperitoneal injection of 200 mg/kg for four days), led to similar results." | ( Taurine and osmoregulation. II. Administration of taurine analogues affords cerebral osmoprotection during chronic hypernatremic dehydration. Del Pizzo, R; Finberg, L; Huxtable, RJ; Sturman, JA; Trachtman, H, 1988) | 0.6 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (71.43) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (33.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||